If you walk into most private biotech company boardrooms today, it is likely that you will hear a discussion about whether to go public. Companies at every stage of development are either getting ready to file for an initial public offering or thinking…

The FTC is reportedly seeking $1 billion from pharmaceutical companies for the role in paying generic companies not to challenge

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
Go to paperABSTRACT: Patent analytical da…

For those who missed the live presentation, here is the discussion of the 2014 Scientific American Worldview scorecard, featuring myself,

Join me on Tuesday March 25th at 11am EST for a discussion of global biotechnology. I will be discussing the

2013 and 2014 have been very good for biotechnology public markets. 35 biotechnology companies went public in 2013, and well

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

Susan Finston’s recent post on redefining protein products has raised some debate on the regulatory status of short peptides. What

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
How DanioLabs has evolved its relationship with the CIMR
Go to paperABSTRACT: The commonest interaction of industry with academia is as the passive recipie…